MELBOURNE, AUSTRALIA – Juno Pharmaceuticals is pleased to announce the acquisition of noradrenaline 2 mg/2 mL and 4 mg/4 mL concentrated injection from Mayne Pharma; an important addition to Juno’s growing range of vasopressors and critical care medicines.
As part of the acquisition, Juno will receive the intellectual property and regulatory approvals for NORADRENALINE MYX 2 mg/2 mL concentrated solution for injection ampoule and NORADRENALINE MYX 4 mg/4 mL concentrated solution for injection ampoule, along with associated contracts and agreements.
This acquisition is Juno’s second for 2019 and is another milestone in Juno’s continued growth and vision to be the leader in supply of off-patent products in hospitals across Australia and New Zealand.
Our focus on hospital injectable medicines and hospital customers makes us ideally placed to supply this product in the Australian market, noted Juno CEO & Managing Director, Mark Crotty. It is exciting to see our range of hospital products growing rapidly, customers see us as their trusted partner in this area.
The agreement comes into effect on July 16th, 2019 and Juno’s Key Account Managers will work closely with customers and wholesalers to ensure a smooth transition and continuity of supply. As with all Juno products, continuous, reliable supply is a top priority.
From July 16th, 2019, all commercial enquiries regarding noradrenaline should be directed to your local Juno representative. Any adverse event reporting, product complaints and medical enquiries should directed to Juno Medical Information on 1800 620 076 email@example.com